LATEST ALERTS
Another company has been warned by the US Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) to stop claiming CBD can cure or mitigate the symptoms of COVID-19
The Court of Justice of the European Union’s (CJEU) decision in the Kanavape case will have a tremendous impact on the CBD industry in the European Union (EU). However, the breadth of its impact is not yet fully realised. A number of things must happen beforehand and it may come down to further court rulings before a baseline level of requirements and » Continue Reading.
While solid research explaining the science behind CBD remains lacking as the market continues to grow, some bad actors in the industry are making false scientific claims for their products
The announcement is a full reversal from the EC on a position that many found surprising in the first place. It marks a stellar period for the regulation of CBD and other cannabinoids with major decisions in their favour at the Court of Justice of the European Union, United Nations and now the EC. The resumption of novel food assessment » Continue Reading.
Overall it seems the industry – particularly in Europe – is not expecting much from Black Friday sales. European companies appear to consider CBD products more as health products that are requirement purchases throughout the year as opposed to lifestyle products that might be purchased as a one off during a special sales event. The situation may be slightly different in the US where Black Friday – » Continue Reading.
How important is the CJEU decision on the Kanavape case? The judgement in favour of CBD from the Courts of Justice of the European Union (CJEU) will almost certainly have significant long-term consequences for the CBD industry in Europe. It will likely influence the European Commission (EC)’s further assessment of the question of whether CBD is a narcotic. The preliminary opinion » Continue Reading.
Aurora Cannabis continues to raise money and issue shares, despite facing allegations of misleading statements in a class-action lawsuit filed by investors
CBD, generally seen as a health or wellness product, and “bad guy” nicotine are almost opposites in terms of public perception – but could putting the two together make commercial sense?
A group of shareholders has filed a class-action lawsuit against Aurora Cannabis, alleging the company “made materially false and misleading statements” about its business, operational, and compliance policies
Expect US Food and Drug Administration (FDA) regulations on CBD by the second half of 2021, according to leading brand Charlotte’s Web
Mexico is overall the number one country to watch, rated highly likely to change regulations on both medical and recreational cannabis in the near future.
Investing activity in the cannabis space is on the rise, as investors take advantage of lower prices and companies seek opportunities to merge – bolstered by anticipated changes at US federal level
It looks like a clean sweep for pro-cannabis referendums in US states. But much work will still need to be done with state legislatures having to design and pass regulatory structures for each measure
Companies do not feel much risk of a glut of CBD-containing food, drink and dietary supplement products or cannabinoid ingredients coming into the UK market if the EU classifies CBD as a narcotic
In short – not a lot in the short-term. The vote in favour of a 0.3% THC limit by the European Parliament (EP) is only the first step in a long process towards actually putting such a change into effect.
The US Food and Drink Administration (FDA) has issued a warning letter to the CBD company For Our Vets over COVID-19 health claims
Holiday sales overall mean more to US companies than their UK counterparts, but the novelty of Black Friday means some are embracing a discount period as a means to create new sales, according to a number of companies
The company of the president of the European Industrial Hemp Association (EIHA) has challenged a ban on the sale of all foods containing CBD
Nestlé has taken a baby step into the European cannabidiol market just a year after creating its own CBD line in the US and will now distribute soft gel CBD capsules in the UK through the Pure Encapsulations brand
Our host for today’s podcast is Jon Bruford, a copy editor at CBD-Intel, who will be joined by CBD-Intel market analyst Maria Alejandra Estanga, who analyses the CBD market for European and American countries. In CBD-Intel’s new podcast, Alejandra discusses global CBD markets and their commonalities and differences, analysing each market and its own peculiarities based on regulations, market development » Continue Reading.
In an unheralded change of Amazon policy, the world’s biggest online marketplace has started allowing the sale of CBD products on its UK site
Matches in Serie A, the top football league in Italy, are for the first time featuring advertisements for a CBD company as the home delivery market continues to grow rapidly in the country
A legal action against Canopy Growth has been halted now that Canadian cannabis cultivator PharmHouse has filed for bankruptcy protection from the Ontario Court while it restructures its business
Commercial interest in mushrooms as active ingredients is on the rise – despite legal issues that severely curtail commercial opportunities
Turbulent times and the ongoing challenges caused by COVID-19 are not stopping some CBD businesses from doing deals and making major investments as they seek expansion into new markets
There has been increased interest in secondary markets that has resulted in some positive developments.
US-based CBD producer Folium Biosciences is looking to tap Asian markets by creating a dedicated stalk extraction line which it believes will meet the strict regulatory requirements of Japan and South Korea
A proposal to be voted on by Brazilian legislators in the coming weeks could legalise the growing of hemp for industrial purposes and cannabis for medical use
2020 seems an unlikely year for the emergence of any new industry, yet this is exactly what has happened in Hong Kong, where there are now locally produced CBD food and drink products
A TV advertising campaign for US company cbdMD demonstrates how attitudes towards CBD products are slowly changing in advertising circles – but also how much work remains to be done
Britain’s newfound enthusiasm for CBD products has joined with the passion for alcohol, with some companies are aiming to capitalise on the trend for “drinking less but drinking better” by launching CBD spirits, especially gin
CBD firms are expanding their reach into the wellness market via company acquisitions, distribution deals and new product launches
More than a dozen CBD businesses have given their backing to an investigation of the impact of CBD on liver toxicity levels in order to provide regulatory authorities in the US with reliable new data
Companies seeking licences to produce hemp in the Chinese province of Yunnan face a tightening of the application process, according to some who have successfully negotiated the concealed hurdles
The pharmaceutical side of the cannabinoid industry continues to grow, with several major announcements expanding treatments and blurring boundaries
CBD-Intel managing director, Tim Phillips, discusses the main facts and issues surrounding CBD and Novel Food status in European markets. He presents the key aspects of the delay, the political issues and the impacts released on the European level and the future challenges for the sector.
The bankruptcy stories continue for cannabinoid firms in the US and Canada as businesses struggle to survive in turbulent times
Molson Coors has made its long awaited entry into the cannabis market through the launch of its Truss brand of cannabis drinks made in partnership with cannabis company Hexo
The immediate impact of the decision is a reduction in certainty for CBD firms – not something they need at a time of significantly heightened uncertainty in other areas.
Charlotte’s Web has been denied a US trademark on appeal – a ruling that has serious implications for any company in the CBD sector selling food, drink or dietary supplement products in the US
Expansion plans by two major players suggest confidence in the future of the CBD market in the UK, with one anticipating a continuing rise in sales driven by reactions to the COVID-19 pandemic
A German company is still waiting to hear from the authorities two months after launching new CBD products that could be considered food supplements
The trade body for hemp and CBD in Ireland has accused the Irish government of working in silos and said its lack of intra-governmental communication as well as consultation with stakeholders could lead to the end of the industry in the country
A new special purpose acquisition company (SPAC) operating in the hemp space is expected to start making moves in the near future after raising $150m earlier this year
A US CBD company has taken an unusual approach to advertising to set itself apart from the pack. It is using a spare forceful campaign that actively discourages some people from using its products
Registration in the US FDA National Drug Code (NDC) Directory conveys significant benefits even if the FDA does not specifically approve these items as over-the-counter products, according to a CBD company
Current indications are that the EC is leaning heavily towards the idea that CBD does indeed count as a narcotic under the 1961 Un Convention.
Canadian CBD firm Ignite lost $67m CAD last year and it could go under if it doesn’t get funding soon, auditors warned in an annual report
As tough market conditions continue for cannabinoid firms in the US and Canada, struggling companies are continuing to pursue a range of survival strategies
Current indications are that the EC is leaning heavily towards the idea that CBD does indeed count as a narcotic under the 1961 Un Convention.
Stay up-to-date with key market trends and regulatory news and receive complimentary data on a regular basis.
"*" indicates required fields
Notifications
